ATE375786T1 - Chitin-mikropartikel und ihre medizinische verwendung - Google Patents

Chitin-mikropartikel und ihre medizinische verwendung

Info

Publication number
ATE375786T1
ATE375786T1 AT02758543T AT02758543T ATE375786T1 AT E375786 T1 ATE375786 T1 AT E375786T1 AT 02758543 T AT02758543 T AT 02758543T AT 02758543 T AT02758543 T AT 02758543T AT E375786 T1 ATE375786 T1 AT E375786T1
Authority
AT
Austria
Prior art keywords
medical use
chitin microparticles
gamma
treatment
chitin
Prior art date
Application number
AT02758543T
Other languages
English (en)
Inventor
Peter Strong
Original Assignee
Cmp Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120030A external-priority patent/GB0120030D0/en
Priority claimed from GB0206864A external-priority patent/GB0206864D0/en
Application filed by Cmp Therapeutics Ltd filed Critical Cmp Therapeutics Ltd
Application granted granted Critical
Publication of ATE375786T1 publication Critical patent/ATE375786T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02758543T 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung ATE375786T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120030A GB0120030D0 (en) 2001-08-16 2001-08-16 Chitin Microparticles and their medical uses
GB0206864A GB0206864D0 (en) 2002-03-22 2002-03-22 Chitin microparticles and their medical uses

Publications (1)

Publication Number Publication Date
ATE375786T1 true ATE375786T1 (de) 2007-11-15

Family

ID=26246442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758543T ATE375786T1 (de) 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US7498038B2 (de)
EP (1) EP1416916B1 (de)
JP (1) JP2005501845A (de)
CN (1) CN1543338B (de)
AT (1) ATE375786T1 (de)
AU (1) AU2002324124B2 (de)
CA (1) CA2457027C (de)
DE (1) DE60223037T2 (de)
ES (1) ES2295391T3 (de)
PT (1) PT1416916E (de)
WO (1) WO2003015744A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113835A1 (en) * 2006-04-05 2007-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-allergy compositions
US20080014281A1 (en) * 2006-06-16 2008-01-17 Florida Atlantic University Chitin Micro-Particles As An Adjuvant
WO2007148048A1 (en) 2006-06-20 2007-12-27 Cmp Therapeutics Limited Compositions comprising chitin microparticles and their medical uses
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
CA2667468C (en) 2006-10-30 2015-04-14 Cmp Therapeutics Limited Methods of producing microparticles
CN100531742C (zh) * 2007-01-18 2009-08-26 宁波普爱生物工程有限公司 一种抗肿瘤氨基多糖超细微粒及其制备方法
EP2123261A1 (de) 2008-05-20 2009-11-25 Stallergenes S.A. Speichelklebende Partikelformulierung zur Induzierung von antigenspezifischer Immuntoleranz
EP2328556A4 (de) * 2008-07-30 2013-11-20 Stc Unm Formulierungen mit grossen trägerteilchen für aerosole zur inhalation von trockenpulver
US9005899B2 (en) * 2010-04-01 2015-04-14 Mingchi University Of Technology Chitin-induced immune response based method for diagnosing allergic asthma in patients
WO2011135578A1 (en) * 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
JP2013535513A (ja) * 2010-08-17 2013-09-12 ムコバックス インク． キチン微粒子を含む栄養組成物
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
AU2016273058B2 (en) 2015-06-04 2021-05-20 Amorphical Ltd. Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates
CN109952510A (zh) * 2016-05-13 2019-06-28 应用酵素医学研究所株式会社 收集用于预测过敏发病风险的数据的方法
IL266149B (en) 2016-10-25 2022-08-01 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia
MX2022000947A (es) 2019-07-23 2022-04-26 Amorphical Ltd Carbonato de calcio amorfo para mejorar el rendimiento deportivo.
WO2022212714A1 (en) 2021-04-01 2022-10-06 Becton Dickinson And Company Methods for enhancing specificity and sensitivity of group a streptococcus immunoassay

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5543041A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4873092A (en) * 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JP2824185B2 (ja) * 1993-03-22 1998-11-11 旭化成工業株式会社 魚類免疫賦活剤
JPH07188291A (ja) * 1993-12-27 1995-07-25 Hayashibara Biochem Lab Inc 蛋白質とその製造方法並びに用途
JPH0959164A (ja) * 1995-08-21 1997-03-04 San Five Kk 抗炎症剤
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
WO2002089839A1 (en) 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
DE69712110T2 (de) 1996-07-10 2002-12-12 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., Nottingham Zusammensetzungen zur einführung von genen in epithelzellen
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
JP4097737B2 (ja) 1997-04-07 2008-06-11 ユニチカ株式会社 鼻口腔用抗炎症散布剤
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
GB9800912D0 (en) 1998-01-17 1998-03-11 Danbiosyst Uk New composition
EP1067839A1 (de) * 1998-04-08 2001-01-17 Eli Lilly And Company Pulmonare und nasale verabreichung von raloxifen
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
JP5124066B2 (ja) 1999-03-24 2013-01-23 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
KR100345466B1 (ko) 1999-10-08 2002-07-26 한국과학기술연구원 콜레라 독소 ｂ 소단위로 표면 수식된 마이크로스피어
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001280934A1 (en) 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US6773695B2 (en) 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
WO2002034287A2 (en) 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
WO2003086454A1 (en) 2002-04-18 2003-10-23 Akzo Nobel N.V. Antigen-loaded chitosan microparticles for oral vaccination
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
WO2007148048A1 (en) * 2006-06-20 2007-12-27 Cmp Therapeutics Limited Compositions comprising chitin microparticles and their medical uses

Also Published As

Publication number Publication date
US7498038B2 (en) 2009-03-03
US20090214666A1 (en) 2009-08-27
CN1543338A (zh) 2004-11-03
CA2457027A1 (en) 2003-02-27
WO2003015744A1 (en) 2003-02-27
US20040234614A1 (en) 2004-11-25
US8551501B2 (en) 2013-10-08
JP2005501845A (ja) 2005-01-20
DE60223037T2 (de) 2008-07-24
CA2457027C (en) 2011-10-11
ES2295391T3 (es) 2008-04-16
EP1416916B1 (de) 2007-10-17
CN1543338B (zh) 2010-06-16
PT1416916E (pt) 2008-01-25
EP1416916A1 (de) 2004-05-12
DE60223037D1 (de) 2007-11-29
AU2002324124B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
DE60223037D1 (de) Chitin-mikropartikel und ihre medizinische verwendung
DK1261360T3 (da) Casein-afledte peptider og anvendelser deraf i behandling
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
IL184749A0 (en) Anti-interferon gamma antibodies and pharmaceutical compositions containing the same
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
EP1675549A4 (de) Geschulte nkt-zellen und ihre verwendungen in der behandlung von immunstörungen
DE60042210D1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
NO20060420L (no) 2-aminobenzoylderivater
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
ATE410235T1 (de) Behandlung von ballastwasser
ATE433326T1 (de) Verwendung von löslichem fgl2 als immunosuppressivum